Clinical Outcomes Of The Use Of New Rayone Emv And Rayone Emv Toric Intraocular Lenses

To investigate clinical outcomes obtained from patients who had implanted with Rayner RayOne EMV Intraocular lenses (IOL) which were introduced in the ESCRS meeting in Milan, 2022. These IOLs have a nondiffractive optic that provides patients with a high-quality vision when targeting emmetropia together with monofocal levels of contrast sensitivity and dysphotopsia. This is an essential feature which provides an extra safety advantage for surgeons who would like to provide correction of presbyopia in their practice but fear the drawback of dysphotopsia and glare at night driving which may arise from the use of multifocal and EDOF intra-ocular lenses.

This study include data from 23 patients who had either bilateral or unilateral implantation with RayOne IOLs. The analysis includes the unaided vision unilaterally and bilaterally, developing dysphotopsia symptoms and how much our patients are independent of glasses after having these implants.

This retrospective data collection includes a total of 23 patients (43 eyes) who have been implanted with the Rayner RayOne IOLs. 20 of these patients consisting of 11 male and 9 females had bilateral implantation, while 3 patients, 1 male and 2 female, had unilateral implantation. 7 eyes were implanted with Rayner RayOne Toric lenses.

The target refractive error was around -1.0D in the non- dominant eye and -0.20D in the dominant eye for all the patients.

Data were available preoperatively and postoperatively at 5 days and 6 weeks and include monocular and binocular uncorrected (UDVA) and monocular and binocular uncorrected near visual acuity (UNVA). Presence of dysphotopsia was also assessed.

The average age of the 23 patients was 65 years old.

Mean monocular UDVA of the non-dominant and dominant eye were 0.2 to 0.3 and 0.1 to -0.1 logMAR, respectively. Majority of patients could achieve a binocular UDVA of 0.0 logMAR.

Mean monocular UNVA of the non-dominant and dominant eye were N6 to N8 and N8 to N10 ,respectively. However, the majority of patients could achieve N6 with both eyes.

Only 1 patient reported dysphotopsia, whom had a history of previous LASIK treatment. From this case, no further patients who had LASIK surgery were recommended these lenses.

Clinical outcomes obtained in 23 patients (43 eyes) implanted with the RayOne EMV IOL, including Toric RayOne EMV Toric, show good visual acuity for distance and near vision and provide a good opportunity for patients to achieve spectacle independence without dysphotopsia. The lenses are very forgiving and show a promising future in the subject of cataract surgery.